Foco cáncer de pulmón y oncologÃa gastrointestinal
Foco cáncer de pulmón y oncologÃa gastrointestinal Foco cáncer de pulmón y oncologÃa gastrointestinal
Erlo2nib vs BSC in second line (BR.21): study design Stra2fied by: • Centre • PS 0/1 vs 2/3 • Response to prior Rx (CR/ PR:SD:PD) • Prior regimens (1 vs 2) • Prior pla2num (yes vs no) R A N D O M I S E Erlo@nib* 150 mg daily Placebo ‘150 mg’ daily *2.1 randomisa@on CR=complete response; PR=par@al response SD=stable disease; PD=progressive disease Shepherd, et al. NEJM 2005
Erlo2nib showed overall survival advantage in pre-‐treated NSCLC (BR.21) 100 Erlo@nib (n=488) Placebo (n=243) Survival probability (%) 75 50 25 Median survival (months) 6.7 4.7 HR=0.73 (0.60–0.87), p=0.001* 27% reduc@on in risk of death with erlo@nib 42.5% increase in median survival with erlo@nib 0 0 5 10 15 20 25 30 Survival @me (months) *Adjusted for stra@fica@on factors (except centre) and EGFR status Shepherd, et al. NEJM 2005 Tarceva SmPC
- Page 1 and 2: Protocolos de cáncer de pulmón -
- Page 3 and 4: Eficacia de los citotóxicos co
- Page 5 and 6: Cispla2no + Pemetrexed (CP) vs
- Page 7 and 8: NSCLC: Cisplatino + Pemetrexed Dosi
- Page 9 and 10: Forma de administrar Cisplatino - I
- Page 11 and 12: Cispla2no + Pemetrexed (CP) vs
- Page 13 and 14: Agentes dirigidos contra la ví
- Page 15 and 16: Carbopla2no + Paclitaxel (PC) v
- Page 17 and 18: Bevacizumab extends survival bey
- Page 19 and 20: Carbopla2no + Paclitaxel (PC) v
- Page 21 and 22: Rejilla de decisión: NSCLC Ava
- Page 23 and 24: Atacando el EGFR: La familia H
- Page 25 and 26: Mok T, Wu YL, Thongprasert S,
- Page 27 and 28: Protocolos de cáncer de pulmón -
- Page 29 and 30: TAX320: overall survival Cumula2
- Page 31: JMEI: Eventos adversos AEs (grad
- Page 35 and 36: Protocolos de cáncer de pulmón -
- Page 37 and 38: Supervivencia (%) Observación Pign
- Page 39 and 40: SCLC: Cisplatino + Etopósido Dosis
- Page 41 and 42: Quimioterapia para tumores sólidos
- Page 43 and 44: Colon y recto: Mayo Dosis por metro
- Page 45 and 46: Colon y recto: XELOX (CAPOX) Dosis
- Page 47 and 48: Otros esquemas Cáncer de colon y
- Page 49 and 50: Cáncer de Recto
- Page 51 and 52: Quimioterapia para tumores pancreat
- Page 53 and 54: Vía biliar: Cisplatino + Gemcitabi
- Page 55 and 56: Carcinoma de cérvix uterino: Cispl
- Page 57 and 58: 50 Quimiorradiación concomitante
- Page 59 and 60: Proctitis Radiodermitis Vómito 2,8
- Page 61 and 62: Protocolos usuales de quimiotera
- Page 63 and 64: Protocolos usuales de quimiotera
Erlo2nib vs BSC in second line (BR.21): <br />
study <strong>de</strong>sign <br />
Stra2fied by: <br />
• Centre <br />
• PS 0/1 vs 2/3 <br />
• Response to prior Rx (CR/<br />
PR:SD:PD) <br />
• Prior regimens (1 vs 2) <br />
• Prior pla2num (yes vs no) <br />
R <br />
A <br />
N <br />
D <br />
O <br />
M <br />
I <br />
S <br />
E <br />
Erlo@nib* 150 mg daily <br />
Placebo ‘150 mg’ daily <br />
*2.1 randomisa@on <br />
CR=complete response; PR=par@al response <br />
SD=stable disease; PD=progressive disease <br />
Shepherd, et al. NEJM 2005
Change language